Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest of Estrella Immunopharma, Inc. from 31 Mar 2021 to 30 Sep 2025

Taxonomy & unit: us-gaap: USD
Description: Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.
Summary: Estrella Immunopharma, Inc. quarterly and annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest in USD history and change rate from 31 Mar 2021 to 30 Sep 2025.
Estrella Immunopharma, Inc. Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for the quarter ending 30 Sep 2025 was $4,801,149, a 42% decline year-over-year.
Estrella Immunopharma, Inc. annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2024 was $7,310,098, a 34% increase from 2023.
Estrella Immunopharma, Inc. annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2023 was $11,114,402, a 1114% decline from 2022.
Estrella Immunopharma, Inc. annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2022 was $915,456, a 270% decline from 2021.
Source SEC data: View on sec.gov

Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Trailing 12 Months (USD)

Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Quarterly (USD)

Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, YoY Quarterly Change (%)

Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Annual (USD)

Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, YoY Annual Change (%)

Estrella Immunopharma, Inc. Quarterly Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest (USD)

Period	TTM Value	Value	YoY Chg	Change %	Start Date	End Date	Report	Filed	Fiscal Year	Fiscal Period
Q3 2025		$4,801,149	-$1,424,412	-42%	01 Jul 2025	30 Sep 2025	10-Q	12 Nov 2025	2025	Q3
Q2 2025		$5,544,028	-$1,594,581	-40%	01 Apr 2025	30 Jun 2025	10-Q	12 Aug 2025	2025	Q2
Q1 2025		$2,104,298	-$1,634,768	-348%	01 Jan 2025	31 Mar 2025	10-Q	14 May 2025	2025	Q1
Q3 2024		$3,376,737	-$1,506,240	-81%	01 Jul 2024	30 Sep 2024	10-Q	12 Nov 2025	2025	Q3
Q2 2024		$3,949,447	-$3,894,520	-7090%	01 Apr 2024	30 Jun 2024	10-Q	12 Aug 2025	2025	Q2
Q1 2024		$469,530	-$425,670	-971%	01 Jan 2024	31 Mar 2024	10-Q	14 May 2025	2025	Q1
Q3 2023	$2,039,039	$1,870,497	-$1,525,634	-442%	01 Jul 2023	30 Sep 2023	10-Q	14 Nov 2024	2025	Q1
Q2 2023	$513,405	$54,927	+$304,659	+85%	01 Apr 2023	30 Jun 2023	10-Q	01 Aug 2023	2023	Q2
Q1 2023	$818,064	$43,860	+$97,392	+69%	01 Jan 2023	31 Mar 2023	10-Q	18 May 2023
Q4 2022	$915,456	$69,755	+$66,042	+49%	01 Oct 2022	31 Dec 2022	10-K	14 Mar 2023	2022	FY
Q3 2022	$981,498	$344,863	-$237,316	-221%	01 Jul 2022	30 Sep 2022	10-Q	14 Nov 2022	2022	Q3
Q2 2022	$744,182	$359,586	-$356,031	-10015%	01 Apr 2022	30 Jun 2022	10-Q	01 Aug 2023	2023	Q2
Q1 2022	$388,151	$141,252	-$140,433		01 Jan 2022	31 Mar 2022	10-Q	18 May 2023
Q4 2021	$247,718	$135,797			01 Oct 2021	31 Dec 2021	10-K	14 Mar 2023	2022	FY
Q3 2021		$107,547			01 Jul 2021	30 Sep 2021	10-Q	14 Nov 2022	2022	Q3
Q2 2021		$3,555			01 Apr 2021	30 Jun 2021	10-Q	08 Aug 2022	2022	Q2
Q1 2021		$819^*			06 Jan 2021	31 Mar 2021	10-Q	16 May 2022	2022	Q1

Period	Value	YoY Chg	Change %	Start Date	End Date	Report	Filed	Fiscal Year	Fiscal Period
2024	$7,310,098	+$3,804,304	+34%	01 Jul 2023	30 Jun 2024	10-KT	25 Mar 2025	2024	FY
2023	$11,114,402	-$10,198,946	-1114%	01 Jul 2022	30 Jun 2023	10-K	27 Sep 2024	2024	FY
2022	$915,456	-$667,738	-270%	01 Jan 2022	31 Dec 2022	10-K	14 Mar 2023	2022	FY
2021	$247,718			06 Jan 2021	31 Dec 2021	10-K	14 Mar 2023	2022	FY

* An asterisk sign (*) next to the value indicates that the value is likely invalid.